- Premium Stock Alerts
- Posts
- Pre-Market Prime: Stocks Set for Big Gains!
Pre-Market Prime: Stocks Set for Big Gains!
Noor Saba
June 18, 2024
You are receiving this newsletter as a subscriber to Premium Stock Alerts
Hello Part-time Trader…👋
Premium Stock Alerts is here with your pre-market cheat sheet. In today's issue, we delve into:
Fed's Latest Announcements: Understand the Federal Reserve's recent decisions and economic outlook, and how they might influence the markets.
Volume Anomalies: Identify stocks witnessing unusual trading volumes, pointing to potential opportunities or risks.
Top Pre-Market Movers: Identify early winners poised for a strong market opening.
Market Indices & Sector Overview: Get a snapshot of key market indices and sector performances to gauge the day's potential trends.
FDA Approvals & Upcoming Decisions: Keep an eye on the latest FDA approvals and crucial upcoming decisions affecting biotech and pharmaceutical stocks.
Now, let's dive into today's edition for a closer look at the insights and analysis that will shape your trading decisions.
🎁 Looking for More? Check out these complementary newsletters for diverse perspectives:
|
Happening Today
✓ 08:30 AM ET – Retail Sales (MoM) (May)
✓ 09:15 AM ET – Industrial Production (MoM) (YoY) (May)
✓ 10:00 AM ET – Business Inventories (MoM) (Apr)
✓ 10:00 AM ET – U.S. Retail Inventories Ex Auto (Apr)
✓ 01:00 PM ET – 20-Year Bond Auction
Sponsored
Jeff Bezos's Plan Exposed
Located 30 miles from Baltimore - Jeff Bezos has been quietly investing in one tiny company that's ground zero of a technology revolution that's going to change everything. Bank of America said the technology would be, "Bigger than fire and bigger than all the revolutions that humanity has seen."
And for investors who get in now profits could be massive - click here for full story.
PREMARKET SNAPSHOT 📈
Market futures are showing slight changes, with the S&P 500 down 0.01%, the Dow decreasing 0.06%, and the NASDAQ up 0.16%.
S&P500$5478.00 ⬇️ -0.01% | Dow$38794.00 ⬇️ -0.06% | NASDAQ$19953.25 ⬆️ 0.16% |
SECTOR SNAPSHOT ✨
Strong market performance driven by Consumer Discretionary and Information Technology, while Health Care and Utilities lag behind.
NAME | PRICE | %CHANGE |
|---|---|---|
Consumer Discretionary | 1,469.92 | +1.43% 🟢 |
Consumer Staples | 826.15 | +0.99% 🟢 |
Energy | 669.07 | +0.22% 🟢 |
Financials | 679.75 | +0.81% 🟢 |
Health Care | 1,693.22 | -0.20% 🔴 |
Industrials | 1,033.35 | +1.08% 🟢 |
Materials | 562.40 | +0.70% 🟢 |
Real Estate | 238.61 | -0.70% 🔴 |
Information Technology | 4,441.29 | +1.18% 🟢 |
Communication Services | 305.17 | +0.39% 🟢 |
Utilities | 348.78 | -1.14% 🔴 |
Sponsored
7 Proven Winners to Buy and Hold Forever
Every powerhouse name on this list is already a proven winner. You won't find any risky moonshots, startups, or unicorns. Just best-in-class blue chips you can hold for years to come.
Get the complete list FREE for a limited time
PreMarket Unusual Volume Stocks
📈 ENDRA Life Sciences Inc (NDRA) jumped 34.17% to $0.14 on a whopping 228.62 million shares traded.
📈 Investors went wild, sending AgriFORCE Growing Systems ltd (AGRI) stock soaring 9.04% to $0.09 on a massive volume of 166.69 million shares after the company released a share repurchase program.
📈 Abnormal activity shook NLS Pharmaceutics Ltd (NLSP), pushing it up 30.18% to $0.15 on a whopping 51.25 million shares traded.
📈 Interactive Strength Inc (TRNR) stock recently closed 70.73% upper at $4.90 on a substantial volume of 44.52 million shares following a reverse stock split.
📈 Polestar Automotive Holding UK PLC ADR (PSNY) increased by 23.96% in a single trading session, with an abnormally high trading volume of 39.55 million shares. The company reported that it is expanding its commercial footprint and retail operations across existing and new markets, as its model line-up continues to grow.
Sponsored
Nvidia's NEW "Silent Partners"
Many companies partnering with Nvidia have seen their own stocks go up...
That includes ASML, up as much as 471%...
Super Micro Computer, which has surged as much as 3,244%.
And Taiwan Semiconductor, which has soared as much as 4,744%.
With Nvidia now pivoting to a new $1 trillion AI superproject...
A new set of partners appear to be poised to benefit.
Find out who they are right away.
Premarket Picks
Actelis Networks, Inc. (ASNS) shares skyrocketed an impressive 101.73% to $2.32 after the company announced a partnership with Carahsoft Technology Corp., a leader in government IT solutions.
Sonoma Pharmaceuticals, Inc. (SNOA) investors saw a welcome rise in pre-market trading, with the stock price climbing 11.51% to $0.1879. This positive movement followed the company's release of its fiscal year and fourth quarter 2024 financial results.
Greenwave Technology Solutions, Inc. (GWAV) also enjoyed a pre-market boost, with its share price rising 11.35% to $2.06. This positive shift came on the heels of news that the company successfully addressed listing compliance concerns raised by The Nasdaq Stock Market LLC.
Below is a list of other hot stocks in pre-market today:
Pre Market Gainers | Pre Market Change | Pre Market Volume |
|---|---|---|
QLGN | +1.77% | 5.12M |
ASNS | +100.00% | 4.47M |
SNOA | +11.16% | 3.55M |
MLGO | +29.86% | 862.87K |
GWAV | +9.73% | 753.27K |
KTRA | +17.77% | 507.41K |
CHGG | +19.54% | 297.76K |
SOAR | +5.29% | 219.52K |
JDZG | +5.52% | 190.81K |
RKLB | +3.92% | 156.22K |
Sponsored
AI's NEXT Magnificent Seven
The Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.
But the Man Who Called Nvidia at $1.10 Says "AI's Next Magnificent Seven Could Do It Even Faster."
See His Breakdown of the Seven Stocks You Should Own Here.
Important FDA
Recently Announced
In a significant development for both Eli Lilly and Co. (LLY) and Alzheimer's patients, a Food and Drug Administration (FDA) panel unanimously recommended approval of Donanemab for the treatment of early symptomatic Alzheimer's disease on June 10, 2024. This marks a promising step forward in the fight against this debilitating disease.
Positive news also arrived for Genfit S.A. (GNFT) on June 11, 2024. Their drug Elafibranor received accelerated approval from the FDA for the treatment of Primary Biliary Cholangitis (PBC), offering new hope for patients battling this chronic liver condition.
Bristol-Myers Squibb (BMY) has reason to celebrate as the FDA granted expanded approval for their drug Augtyro on June 13, 2024. Augtyro is now indicated for the treatment of patients with NTRK-positive locally advanced or metastatic solid tumors, representing a broader application of this targeted therapy.
Sponsored
Only own the best: 7 stocks poised for greatness in 2024
The uncertainty rattling the markets is off the charts.
But according to one of America's leading tech investors, if you're looking to protect your portfolio from the chaos and even significantly grow it in 2024...
You need to own these 7 stocks.
Click for FREE report.
Upcoming Announcements
Merck (MRK) awaits the FDA's verdict on their sBLA for KEYTRUDA, a treatment for endometrial carcinoma that combines KEYTRUDA with chemotherapy.
argenx (ARGX) is anxiously awaiting the FDA's decision on their sBLA for VYVGART Hytrulo, hoping to expand its use for treating Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
Sarepta Therapeutics (SRPT) is looking for the FDA's green light on its BLA for ELEVIDYS, seeking to convert its current accelerated approval to full approval.
🎁 Looking for More? Check out these complementary newsletters for diverse perspectives:
|
Happy investing,
Maeve Grace
Editor In Chief
Premium Trade Alerts
Important: This newsletter does not provide investment advice. The stocks mentioned should not be taken as recommendations. Your investments are solely your decisions.
Disclosure: I hold no positions in any companies mentioned, either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article.
Reply